Tests SI-053 with standard care in adults with new glioblastoma

Tests a temozolomide-based drug, SI-053, given into the brain with standard care.

Plain-language title generated from the registry record
Registry title: An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).

Key facts

Where

Aachen, Cologne, and Hamburg, GermanySee the 3 sites

Phase

Phase 1